PRSRT STD U.S. Postage PAID Minneapolis, MN Permit No. 29418 Demos Medical Publishing 11 West 42nd Street New York, NY 10036 SAVE 15% PLUS FREE SHIPPING WHEN YOU ORDER ONLINE BY JUNE 30, 2011* ON ORDERS OVER $29.00 www.demosmedpub.com VISIT AMAZON, BN.COM AND GOOGLE BOOKS TO FIND DEMOS MEDICAL TITLES IN A VARIETY OF E-BOOK FORMATS. SAVE 15% PLUS FREE SHIPPING WHEN YOU ORDER ONLINE BY JUNE 30, 2011* ON ORDERS OVER $29.00 DEMOS MEDICAL PUBLISHING ONCOLOGY 2011 Visit Amazon, bn.com and Google Books to find Demos Medical titles in a variety of e-book formats.
Transcript
PRSR
T ST
DU
.S. P
osta
gePA
IDM
inne
apol
is, M
NPe
rmit
No.
294
18
Dem
os M
edic
al
Pu
blish
ing
11
Wes
t 4
2n
d S
tree
tN
ew Y
ork
, NY
10
03
6
Sa
ve
15
%
Pl
uS
Fr
ee
Sh
iPP
ing
Wh
en
Yo
u o
rd
er
on
lin
e
bY
Ju
ne
30
, 20
11*
ON
Or
de
rS
Ov
er
$2
9.0
0
www.demosmedpub.com
viSit aMazon, bn.coM aNd google bookS tO fiNd
DeMoS MeDical titleS iN a varietY Of e-bOOk fOrmatS.
Save 15% PluS Free ShiPPing
When You order online bY June 30, 2011*
ON OrderS Over $29.00
demOS medical PubliShiNg
oncologY 2011
Vis
it A
maz
on
, bn
.co
m a
nd
Go
og
le b
oo
ks t
o fi
nd
de
mo
s M
ed
ical
tit
les
in a
var
iety
of
e-b
oo
k fo
rmat
s.
demOS medical PubliShiNg | onColoGY | 2011
free shippinG* *on orders oVer $29.00
demOS medical PubliShiNg | onColoGY | 2011
WheN YOu Order ONliNe Or call 1-800-532-8663tO Order viSit www.demosmedpub.com
Forthcoming in Oncology
Tumor board reviewsGuidelines and Case reviews in oncologyEdited by Robert F. Todd, III, MD, PhD, Chair of Medicine, Baylor College of Medicine, Kathleen A. Cooney, MD, Chief of Hematology/Oncology, Michigan University School of Medicine, Teresa Hayes, MD, Assistant Professor of Oncology, Baylor College of Medicine, Martha Pritchett Mims, MD, Chief of Hematology/Oncology, Baylor College of Medicine, and Francis P. Worden, MD, Clinical Associate Professor of Oncology and Fellowship Director, Michigan University School of Medicine
Tumor Board Reviews provides comprehensive coverage of all topics in oncology. Each topic is introduced with a short overview, followed by a sequence of specific presentations organized by disease classification. Each disease classification includes a concise summary of current practice standards followed by a “tumor board” case presentation. These case presentations demonstrate clinical applica-tions and are accompanied by expert comment and teaching points drawn from the case.
The combination of guideline summaries with cases illustrating clinical applica-tions is unique. Guidelines (mostly issued through NCCN) are issued and updated continually but often there is no real explanation of how they should be applied. The combination of guidelines summaries with case discussions make this volume a unique tool for keeping current with clinical guidelines and provides the reader with a clear understanding of applications of new information for use in daily practice.
FeATuRes OF TumoR BoaRd Reviews InCluDe:
r Comprehensive coverage of all areas of oncology
r Presentation of most recent guidelines and management standards in concise, user-friendly format
r In depth “tumor board” presentations showing clear clinical applications
r Special focus on indications and use of new drugs, and treatment of new side effects
december 2011 • 400 pp • hardcover • 978-1-936287-17-8 e-book isbn • 978-1-617050-46-6 • $95.00 / $80.75
Forthcoming in Oncology
neurologic complications of cancer TherapyEditors: Patrick Y. Wen, MD, Director, Division of Neuro-Oncology, Brigham & Women’s Hospital, David schiff, MD, Co-Director, Neuro-Oncology Center, University of Virginia, and eudocia C. Quant, MD, Neurology Fellow, Brigham & Women’s Hospital
Neurologic side effects of cancer therapy can inhibit treatment, can be dose-limiting and can diminish quality-of-life. Neurotoxicity related to cancer therapy is a common problem in oncology practice and in clinical neurology. Recognition of neurologic complications of anticancer therapy is necessary due to potential confusion with metastatic disease, paraneoplastic syndromes or comorbid neurologic disorders that do not require reduction or discontinuation of therapy.
Neurologic Complications of Cancer Therapy provides comprehensive coverage of the recognition and management of neurologic symptoms related to cancer therapy. The book includes sections on systemic therapy discussed by both agent and adverse event. The section on adverse events is particularly valuable to clinicians, allowing them to consult by symptom in cases where multiple agents have been administered and the source of the complication is uncertain. The systemic therapy section includes coverage of immunologic agents, biologics, and targeted therapies. The book also features sections on the complications of radiation therapy, complications of surgery and high-dose chemotherapy, and stem cell transplantation.
NeuRologiC CompliCaTioNs of CaNCeR TheRapy FeATuRes:
r A widely recognized team of editors
r Systemic therapy covered by therapeutic agent and by adverse event, enabling a “problem-oriented” approach for the clinician
r Coverage of newer modalities including immunologic agents, biologics, and targeted therapies
r Complete sections on complications of radiation therapy, surgery, high-dose chemotherapy, and stem-call transplantion
conTenTS: PART 1: neuROlOgIC COMPlICATIOns OF sYsTeMIC THeRAPIes: ACCORDIng TO AgenT: 1. Alkylating agents; 2. Antimetabolites 3. Plant Alkaloids; 4. Topoisomerase inhibitors; 5. Epothilones; 6. Amino acid degraders; 7. Corticosteroids; 8. Immunomodulatory agents; 9. Immu-nosuppressants; 10. Biologic Agents; 11. Targeted Therapies; 12. Hormonal therapies; 13. Supportive therapies; According to adverse event: 14. Cognitive function; 15. Central nervous system complications (except cognitive dysfunction); 16. Peripheral nervous system complications (excluding muscle and NMJ disorders); 17. Neuromuscular junction and myopathy; PART 2: neuROlOgIC COMPlICATIOns OF RADIATIOn THeRAPY: 18. Mechanisms of radiation damage; 19. Early CNS complications; 20. Late-delayed CNS complications; 21. Radiation-induced tumors; 22. Radiation vasculopathy; 23. Spinal cord damage; 24. Peripheral nerve damage; PART 3: neuROlOgIC COMPlICATIOns OF suRgeRY: 25. Surgery; PART 4: neuROlOgIC COMPlICATIOns OF HeMATOPOIeTIC sTeM Cell TRAns-PlAnTATIOn: 26. Hematopoietic stem cell transplantation
september 2011 • 350 pp • hardcover • 978-1-932687-07-9 e-book isbn • 978-1-617050-19-0 • $99.00 / $84.15
32
demOS medical PubliShiNg | onColoGY | 2011
free shippinG* *on orders oVer $29.00
demOS medical PubliShiNg | onColoGY | 2011
WheN YOu Order ONliNe Or call 1-800-532-8663tO Order viSit www.demosmedpub.com
Forthcoming December 2011
Prostate cancerJames l. gulley, MD, PhD, FACP, Director Clinical Trials Group, Laboratory of Tumor Immunology and Biology, National Cancer Institutedecember 2011 · 200 pp · hardcover · 978-1-936287-46-8 • e-book isbn 978-1-935281-91-7 · $85.00 / $72.25
leukemiaGuest Editor: uday R. Popat, MD, Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX
Leukemia treatment has undergone major change over the course of the past few years and leukemia addresses current best practices in the light of the most recent evidence.
All of the chapters are written by international experts in the field, address the common clinical scenarios in leukemia and are multidisciplinary in scope covering surgical, medical, immunother-apy, and stem cell transplantation. Chapters examining novel and targeted therapies, infections, and reduced intensity allogeneic transplantation round out the coverage.conTenTS: 1. Hematopathology and Diagnostic Studies, 2. Acute Myeloid Leukemia, 3. Chronic myeloid Leukemia, 4. Acute Lymphoblastic Leukemia in Adults, 5. Acute Promyelocytic Leukemia, 6. Myelodysplastic Syndrome, 7. Myeloproliferative Disorders, 8. Chronic Lymphocytic Leukemia, 9. Reduced intensity Allogeneic Transplantation in Leukemia,10. Alterna-tive Donor Stem Cell Transplantation in Patients with Leukemia, 11. Immunotherapy in Leukemia, 12. Novel and Targeted Therapy in Leukemia, 13. Infections in Patients with Leukemia
August 2011 • 200 pp • hardcover • 978-1-933864-68-6 • e-book isbn 978-1-935281-42-9 • $85.00 / $72.25
renal cancerGuest Editor: Walter M. stadler, MD, Fred C. Buffet Professor of Medicine and Surgery, Associate Dean for Clinical Research, Director, Genitourinary Program, The University of Chicago Medical Center
Renal cancer treatment has undergone major changes over the course of the past few years and Renal Cancer addresses current best practices in the light of the most recent evidence. All of the chapters are written by international experts in the field, address the common clinical scenarios in renal cancer and are multi-disciplinary in scope covering surgical, medical, and radiation therapy. Chapters examining emerging and novel therapeutic targets, and the management of both CNS, and skeletal metastases in renal cancer round out the coverage.
conTenTS: 1. The Biology of Renal Cancer, 2. Renal Cell Carcinoma: Current Concepts of Morphologic Subclassification and Clinical Relevance, 3. Imaging Renal Carcinoma, 4. Management of Small Renal Masses 5. Surgical Management of Renal Cancer, 6. Nonsystemic Approaches to the Management of Metastatic Renal Cell Carcinoma, 7. IL-2 and Other Immunotherapy in Renal Cancer, 8. VEGF Pathway-Directed Therapies in Renal Carcinoma, 9. mTOR Pathway-Directed Agents in Renal Cell Carcinoma, 10. Emerging and Novel Therapeutic Targets in Renal Cancer, 11. Management of Central Nervous System Metasta-ses from Renal Cancer, 12. Evaluation and Management of Skeletal Metastases
April 2011 • 200 pp • hardcover • 978-1-936287-20-8 • e-book isbn 978-1-617050-49-7 • $85.00 / $72.25
emerging Cancer Therapeutics VOluMe 1, 2010
breast cancerGuest Editor: Antoinette R. Tan, MD, MHsc, Assistant Professor of Medicine, The Cancer Institute of New Jersey
Breast Cancer offers a comprehensive and in-depth review of the current literature of breast cancer. Chapters examine risk factors and prevention strate-gies, trends and developments in imaging, surgical management, radiotherapy advances, adjuvant endocrine and chemotherapies, targeted metastatic therapy, and the role of bisphosphonates and novel bone agents in breast cancer.conTenTS: Risk Factors and Strategies for Prevention of Breast Cancer, Current Trends and New Developments in Breast Cancer Imaging, Update on the Surgical Management of Breast Cancer: Areas of Controversy and Advancement, Advances in Radiotherapy for Breast Cancer, Adjuvant Chemotherapy for Breast Cancer: Updates and New Perspectives, Endocrine Therapy for Early Breast Cancer, HER2-Targeted Treatment in the Adjuvant Setting for Breast Cancer, Endocrine Treatment for Meta-static Breast Cancer, Chemotherapy for Metastatic Breast Cancer, Targeted Therapy for Metastatic Breast Cancer, Management of HER2-Positive Metastatic Breast Cancer: Standard and New Approaches, Treatment Options for Triple-Negative Breast Cancer, The Expanding Role of Bisphosphonates and Novel Bone Agents in Breast Cancer, Principles of Breast Cancer Genomics
december 2010 • 200 pp • hardcover • 978-1-936287-14-7 • e-book isbn • 978-1-617050-43-5 • $85.00 / $72.25
Multiple MyelomaGuest Editor: shaji Kumar, MD, Associate Professor of Medicine, Division of Hematology, Mayo Clinic, Rochester
Management options and outcomes for individuals with multiple myelomas, have improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation.
The clinician is better placed to offer effective therapy but at the same time is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data. multiple myeloma provides a comprehensive and in-depth review of this group of malignancies. conTenTS: 1. The Etiology and Pathophysiology of Multiple Myeloma, 2. Genetic Abnormalities in Multiple Myeloma, 3. Mono-clonal Gammopathy of Undetermined Significance, 4. Smoldering Multiple Myeloma, 5. Laboratory Evaluation and Diagnosis of Monoclonal Gammopathies, 6. Prognostic Factors and Risk Stratification in Myeloma, 7. Initial Treatment of Multiple Myeloma in Transplant-Eligible Patients, 8. Current Trends in Hematopoietic Stem Cell Transplantation for Multiple Myeloma, 9. Treatment of Myeloma in Transplant-Ineligible Patients, 10. Relapsed and Refractory Multiple Myeloma, 11. Management of Treatment Complications and Supportive Care
gastrointestinal MalignanciesGuest Editor: M. Wasif saif, MD, MBBs, Associate Professor of Medicine, Medical Oncology, Director, GI Cancers Program, Yale Cancer Center, Yale University School of Medicine Professor of Medicine
“a clinically useful and concise review of a range of current and emerging therapies for gastrointestinal malignancies is presented in this book.” —Doody’s
gastrointestinal malignancies provides a comprehensive and in-depth review of this group of malignancies. This issue reviews the current literature, provides critical evalua-tions of the data, and offers evidence-based recommendations. The chapters update the current screening tools for colon cancers, assessment of predictive markers such as k-Ras and BRAF in the management of colon cancer as well as the state-of-the-art for use of both cytotoxic chemo-therapy and the incorporation of newer biological therapies.conTenTS: 1. Screening of Colorectal Cancer, 2. Assessment of k-RAS and BRAF Mutations in Metastatic Cancer, 3. Esopha-geal Cancer: 3.1 Advances in Surgical Therapy for Esophageal Cancer, 3.2 New Developments in Combined-Modality Therapy, 3.3 New Developments in Radiation Therapy Planning, 3.4 Chemotherapy and Targeted Agents for Stage IV Esophageal Cancer, 4. Gastric Cancer, 5. Hepatocellular Cancer, 6. Colorectal Cancer, 7. Pancreatic Cancer, 8. Gastrointestinal Stromal Cancers, 9. Current Management of Anal Cancer, 10. Small Bowel Adenocarcinoma
A new Cutting-edge Review Publication in Cancer Therapeutics
emerging cancer Therapeutics VOLUME 2, 2011
eDITOR-In-CHIeF: Jame Abraham, MD, FACP, Bonnie Wells Wilson Distinguished Professor and Eminent Scholar, Chief, Section of Hematology-Oncology, and Medical Director, Mary Babb Randolph Cancer Center, West Virginia University
Published three times a year emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.
FeATuRes OF emeRgiNg CaNCeR TheRapeuTiCs InCluDe:
r Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics
r In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics
r Issues edited by an authority in specific subject area
r Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience
emerging Cancer Therapeutics is available by subscription and individual issues. Individual subscriptions include print issue for volume year subscribed to and online access to all back issues.
r North American Individual Subscription Rate: $199.00 / $161.50.
r International Individual Subscription Rate: $225.00 / $191.25
demOS medical PubliShiNg | onColoGY | 2011
free shippinG* *on orders oVer $29.00
demOS medical PubliShiNg | onColoGY | 2011
WheN YOu Order ONliNe Or call 1-800-532-8663tO Order viSit www.demosmedpub.com
approach in breast reconstruction, 10.Multidisciplinary approach in the treatment of metastatic disease, 11.Multidisci-plinary approach in the management of locally recurrent disease, 12.Multidisciplinary approach to the patient’s quality of life, 13.Psychiatric Issues in Breast Cancer, 14.Multidisciplinary considerations: Racial disparities in breast cancer, 15.Multidisciplinary Breast Cancer Care in the Community, 16.Future directions in the treatment of breast cancer
Kemp H. Kernstine, MD PhD, Professor of Surgery, Chairman,Division of Thoracic Surgery, Robert Tucker Hayes Distinguished Chair in Cardiothoracic Surgery, University of Texas, Southwestern School of Medicine and Karen L. Reckamp, MD MS, Assistant Professor of Medicine, Department of Medical Oncology & Exper-imental Therapeutics and Hematology & Hematopoietic Cell Trans-plant, City of Hope Comprehensive Cancer Center and Beckman Research Institute
Over the course of the last decade, the treatment of lung cancer has evolved quite rapidly. New scientific and clinical advances have modified the stan-dard of care and led to improved patient outcomes. At the same time, the treatment of lung cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment.
Lung Cancer, written by a multidisciplinary team of authors representing a range of disciplines, is a valuable resource for physicians, fellows, nurses, physician assistants, physical therapists, and all health care providers involved in the treatment of lung can-cer. Lung Cancer summarizes the state-of-the-art issues related to the treatment of lung cancer and describes an approach for optimal multidisciplinary care for individuals who are at higher risk of or who have been diagnosed with lung cancer.
1. Overview, 2. Multidisciplinary Primary Care Approach to the Management of Lung Cancer: Non-small Cell Lung Cancer, 3. Pathology of Lung Cancer, 4. The New Lung Cancer Staging System, 5. Lung Cancer Screening and Prevention of Cancer, 6. Imaging in Lung Cancer, Treatment According to Stage: 7. Early Stage Local Disease NSCLC, Surgical Therapy Options, 8. Is There a Role for Surgical Treatment in Patients with Local Small Cell Lung Cancer?, 9. Evaluation, Management and Medical Therapy of Small Cell lung Cancer, 10. Stages IB to IIIA NSCLC: The Case for Induction vs. Adjuvant Chemotherapy, 11. Stage IIIA Disease: The Case Against Surgical Involvement, 12. Stage IIIA: The Case for Surgical Involvement, 13. Stage IIIB and IV: Potential Surgical Opportunities to Improve Survival and the Data Supporting This, 14. Stage IIIB and IV Disease NSCLC: Primary Therapy, 15. Stage IIIB and IV Disease NSCLC: Recurrent Disease, 16. Conformal Radiation Therapy for NSCLC and Small Cell Lung Cancer: Primary and Metastatic and Recurrent Disease, 17. Stereotactic Radiation Therapy for Primary and Metastatic and Recurrent Disease, Special Circumstances: 18. Tracheobronchial Cancers: Brachytherapy, Laser Resection, Endobronchial Resection, PDT, 19. Targeting Pathways in NSCLC and SCLS, 20. Role of Personalized Medicine: Now and the Future, 21. Lung Cancer in the Elderly, 22. Lung Cancer in Minorities, 23. Immunological Approaches to the Treatment of Lung Cancer, 24. Multidisciplinary Approach to Palliative Management and Symptom Management of Disease, 25. Multidisciplinary approaches to the Psycho-oncologic Management of Disease, 26. Multidisciplinary Management in the Community Setting, 27. Future Directions in the Multidisciplinary Management of Lung Cancer
1.Importance of the multidisciplinary approach to breast cancer, 2.Multidisciplinary approach to the preven-tion & screening of breast CA, 3.Intake of new patients for Multidisciplinary Clinics, 4.Multidisciplinary issues for newly diagnosed patients, 5.””Medical and Surgical Management of Atypical Hyperplasia and Lobular Carcinoma in situ, 6.Multidisciplinary approach in the treatment of Ductal Carcinoma in situ, 7.Multidisciplinary approach in the treatment of early breast cancer, 8.Multidisciplinary approach in the treatment of locally advanced breast cancer, 9.Multidisciplinary
76
Alphonse G. Taghian, MD,PhD, Associate Professor of Radiation Oncology, Harvard Medical School, Chief of Breast Service, Mas-sachusetts General Hospital, Barbara L. Smith, MD, PhD, Associ-ate Professor of Surgery, Harvard Medical School, Director, Breast Program, Massachusetts General Hospital, and John K. Erban, MD, Associate Professor of Medicine, Harvard Medical School, Director, Clinical Programs and Co-Director, Gillette Center for Breast Cancer, Massachusetts General Hospital
Over the course of the last decade, the treatment of breast cancer has evolved quite rap-idly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of breast cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, fertility radiation, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment.
Breast Cancer, by a multidisciplinary team of authors representing a range of disci-plines, is a review for physicians, fellows, nurses, physician assistants, physical thera-pists, and all health care providers involved in the treatment of breast cancer. Breast Cancer summarizes the state-of-the-art issues related to the treatment of breast cancer and describes an approach for optimal multidisciplinary care for women who are at higher risk of or who have been diagnosed with breast cancer.
Current Multidisciplinary Oncology
lung cancera multidisciplinary approach to diagnosis and management
october 2010 • 272 pp • hardcover • 978-1-936287-06-2 • e-book isbn • 978-1-617050-18-3 • $125.00 / $106.25
Multidisciplinary approach to Prostate cancera multidisciplinary approach to diagnosis and managementAdam Dicker, MD, PhD, Chairman, Radiation Oncology, William Kevin Kelly, DO, Professor of Medical Oncology, edouard Trabuski, MD, all of Jefferson Medical College
breast cancer a multidisciplinary approach to diagnosis and management
current Multidisciplinary oncologyseRIes eDITOR: Charles R. Thomas, Jr., MD, Professor and Chairman, Depart-ment of Radiation Medicine, and Professor of Hematology/ Oncology, Knight Cancer Institute, Oregon Health Sciences University
The Current multidisciplinary oncology series consolidates and integrates the varied aspects of multidisciplinary care for major topics in oncology, including breast, lung, prostate, head and neck and more.
The volumes in the Current multidisciplinary oncology series represent all related topic areas, including oncology, radiation oncology, pain, pathology, imaging, psycho-logical support and the primary disease. In addition, each volume include a chapter focusing on special populations and the disease’s impact / difference on them, discussion of Future Directions and Quality of Life issues, and each volume a chapter written by a private practice oncologist
A new Resource That Will Aid in the Multidisciplinary Approach to solid Tumors
demOS medical PubliShiNg | onColoGY | 2011
free shippinG* *on orders oVer $29.00
demOS medical PubliShiNg | onColoGY | 2011
WheN YOu Order ONliNe Or call 1-800-532-8663tO Order viSit www.demosmedpub.com
Gregory M.M. Videtic, MD, CM, FRCPC, Residency Program Di-rector, and Associate Professor of Medicine, Department of Radiation Oncology, and Andrew D. Vassil, MD, Resident Physician, Depart-ment of Radiation Oncology, both of the Cleveland Clinic Foundation
The Handbook of Radiation Treatment Delivery is a focused pocket-sized handbook designed for Radiation Oncology trainees and residents, to serve as an up-to-date, quick resource to lead them through all of the standard steps to plan and deliver radiotherapy for
all major malignancies. The goal of the Handbook is to provide evidence-based information but also to be reflective of the knowledge gained through experience in practice. All chap-ters represent a joint collaboration between residents and staff radiation oncologists, in the Department of Radiation Oncology at the Cleveland Clinic.
Throughout the Handbook, the focus is on a series of steps to follow in order to successful-ly complete effective radiotherapy planning. Sections are organized by body site or system, whichever proved best for consistency in presenting the general principles of planning. Also included are specialized topics such as palliative therapy and pediatrics. After a discussion of general planning requirements, each specific subsite within a given section then provides more specific details on approaches to radiotherapy planning.
1. General Physics Principles, 2. Tools for Simulation and Treatment, 3. Central Nervous System Radiothera-py, 4. Head and Neck Radiotherapy, 5. Breast Radiotherapy, 6. Thoracic Radiotherapy, 7. Gastrointestinal (Nonesophageal) Radiotherapy, 8. Genitourinary Radiotherapy, 9. Gynecologic Radiotherapy, 10. Lymphoma and Myeloma Radiotherapy, 11. Soft Tissue Sarcoma Radiotherapy, 12. Pediatric Radiotherapy, 13. Palliative Radiotherapy
Robert I. Haddad, MD, Clinical Director, Head and Neck Oncology, Dana Farber Cancer Institute, Harvard Medical School.
The treatment of head and neck cancer is extremely challenging and in-volves insight and expertise from multiple disciplines. Multidisciplinary Management of Head and Neck Cancer is a comprehensive textbook looking at different aspects of head and neck cancer, including the diag-nosis, treatment, and outcomes for patients with this disease. The chapters written by world-renowned experts cover the entire discipline of head and
neck oncology and include discussion of the role of HPV infections, advances in radiotherapy, new surgical techniques, novel agents in thyroid therapy and more. The book is designed to be both practical and comprehensive for the physicians treating this complex disease.
FEATURES OF MULTIDISCIPLINARY MANAGEMENT OF HEAD AND NECK CANCER INCLUDE:
A chapter on the role of HPV infections in head and neck cancer
A chapter on new advances in radiotherapy for head and neck cancer, including review of IMRT, new standards and potential pitfalls
Detailed discussion of the role of chemotherapy in head and neck cancer, including commonly used drugs and how to combine them with radiotherapy to improve patient outcomes
Detailed discussion on incorporating novel agents with radiotherapy
Detailed discussion of novel therapeutics in head and neck cancer, including new drugs and biologics 1. Role of HPV infections in head and neck cancer, 2.New advances in radiotherapy for head and neck cancer, 3.
Molecularly Targeted Agents in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck, 4. Induction chemo-therapy in locally advanced head and neck cancer: an evolving concept, 5. New surgical techniques in head and neck cancer, 6. Incorporating novel agents with chemotherapy and radiotherapy for the treatment of locally advanced squamous cel carcinoma of the head and neck, 7. Concurrent chemoradiotherapy in head and neck cancer, 8. Novel agents in thyroid cancer, 9. Prevention and treatment of dysphagia and aspiration in head and neck cancer, 10. Functional imaging of the head and neck with positron emission tomography (PET), 11. Diagnostic and therapeutic advances in multidisciplinary care for nasopharyngeal cancer
New and Forthcoming Titles in Oncology
98
november 2010 • 232 pp • hardcover • 978-1-933864-55-6 • e-book isbn • 978-1-617050-12-1 • $85.00 / $72.25
september 2010 • 260 pp • hardcover • 978-1-933864-52-5 • e-book isbn • 978-935281-58-0 • $75.00 / $63.75
handbook of Treatment Planning in radiation oncology
Multidisciplinary Management of head and neck center
october 2010 • 1,024 pp • 48 page Color insert hardcover • 978-1-933864-78-5 • e-book isbn 978-1-617050-14-5 • $245.00 / $208.25
EDITOR-IN-CHIEF: Minesh P. Mehta, MD, FASTRO, Professor, Department of Human Oncology, University of Wisconsin
EDITORS: Susan M. Chang, MD, Professor, Vice Chair of Neurological Surgery, Director, Division of Neuro-On-cology, University of California San Francisco, Abhijit Guha, MSc, MD, FRCSC, FACS, Professor of Surgery (Neurosurgery), Toronto Western Hospital, Hudson Chair in Neuro-Oncology, University of Toronto, Herbert B. Newton, MD, FAAN, Professor of Neurology, Neurosurgery, and Oncology, Esther Dardinger Endowed Chair in Neuro-
Oncology, Department of Neurosurgery, Dardinger, Neuro-Oncology Center, Ohio State Univer- sity Medical Center and Michael A. Vogelbaum, MD, PhD, FACS, The Robert and Kathryn Lamborn Chair for Neuro-Oncology, Department of Neurological Surgery, Cleveland Clinic
Neuro-oncologic (brain and spine) cancers account for 19,000 new cases and 13,000 deaths per year. The early and proper diagnosis of these virulent cancers is critical to patient out-comes and diagnosis and treatment strategies are continually evolving.
The multidisciplinary team that manages these patients involves medical and radiation oncology, neurosurgery, neuroimaging, nurses and therapists.
Principles and Practices of Neuro-Oncology establishes a new gold standard in care through a comprehensive and multidisciplinary text covering all aspects of neuro-oncology. Six major sections cover all topics related to epidemiology and etiology, clinical features and supportive care, imaging, neuroanatomy and neurosurgery, medical oncology and targeted therapies, and radiation oncology for adult and pediatric cancers. Expert contributors from multiple disciplines provide detailed and in-depth discussions of the entire fi eld of neuro-oncology including histopathologic harmonization, quality of life and therapeutic changes in terms of combined modality treatments, advanced radiation techniques, the advent of new drugs, especially targeted agents, and the tantalizing early promise of personalized thera-peutic approaches.
With contributions from over 180 authors, numerous diagrams, illustrations, and tables and 48-page color plate section, Principles and Practices of Neuro-Oncology refl ects the breadth and depth of this multi-faceted specialty.
PART I: EPIDEMIOLOGY; Section Editors: Margaret R. Wrensch MPH, PhD, Professor, Department of Neurological Surgery, University of California, San Francisco, Judith A. Schwartzbaum, PhD, Associate Professor, Divi-sion of Epidemiology, College of Public Health, The Ohio State University, and Melissa Bondy, PhD, Professor, Depart-ment of Epidemiology, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center
PART II: MOLECULAR BIOLOGY; Section Editor Abhijit Guha, Professor of Surgery (Neurosurgery), Toronto West-ern Hospital, Senior Scientist and Co-Director, The Arthur and Sonia Labatt Brain Tumour Research Centre Hospital for Sick Children, Hudson Chair in Neuro-Oncology, University of Toronto
PART III: CLINICAL PRESENTATION AND SUPPORTIVE CARE; Section Editor: Herbert B. Newton, Professor of Neurology, Neurosurgery, and Oncology, Esther Dardinger Endowed Chair in Neuro-Oncology, Department of Neuro-surgery, Dardinger Neuro-Oncology Center, The Ohio State University Medical Center, James Cancer Hospital
PART IV: NEUROANATOMY AND NEUROSURGERY; Section Editor: Michael A. Vogelbaum, Associate Director of Neurosurgical Oncology, Department of Brain Tumor and Neuro-Oncology Center, Cleveland Clinic/Neurosurgery
PART V: MEDICAL ONCOLOGY; Section Editor: Susan M. Chang, Professor, Vice Chair, Neurological Surgery Direc-tor, Division of Neuro-Oncology, University of California, San Francisco
PART VI: RADIATION THERAPY; Section Editor: Minesh P. Mehta, Professor, Department of Human Oncology, University of Wisconsin
Principles and Practice of neuro-oncologya multidisciplinary approach to diagnosis and management
new Titles in Oncology new Titles in Oncology
demOS medical PubliShiNg | onColoGY | 2011
free shippinG* *on orders oVer $29.00
demOS medical PubliShiNg | onColoGY | 2011
WheN YOu Order ONliNe Or call 1-800-532-8663tO Order viSit www.demosmedpub.com
major tool in the management of the disease. prostate Cancer includes reviews of all major recent advances in treatment of favorable, intermediate and high-risk prostate cancer as well as newer modalities such as brachytherapy, stereotactic body radiation therapy, and proton beam ra-diotherapy. Articles also review current knowledge in the areas of new biomarkers, risk stratifica-tion, and risk stratification. This issue provides the practitioner with a full current overview of the present best practices and recent research in management of this complex and challenging disease. conTenTS: 1.New Biomarkers in Prostate Cancer: A Radiation Oncology Perspective 2. Risk Stratification in Nonmeta-static Prostate Cancer: Implications for Treatment, 3. Treatment of Favorable- Risk Prostate Cancer, 4. Intermediate Risk Prostate Cancer: Role of Androgen Deprivation, 5. High-Risk Prostate Cancer 6 Duration and Timing of Neoadjuvant/Adjuvant Androgen Deprivation in Nonmetastatic Prostate Caner, 7. Current Role of Salvage and Adjuvant Radiotherapy for Prostate Cancer, 8. Prostate Brachytherapy, 9. Stereotactic Body Radiation for Prostate Cancer, 10. Proton Therapy for the Treatment of Prostate Cancer, 11. Image-Guided Strategies for Prostate Cancer, 12. Treatment of Intermediate-Risk Prostate Cancer , 13. Chemoprevention in Prostate Cancer: Current Clinical Evidence, 14. Quality-of-Life Issues in the Radiotherapeutic Management of Localized Prostate Cancer
April 2011 • 184 pp • hardback • 978-1-936287-33-8 • e-book isbn • 978-1-617050-67-1 • $85.00 / $72.25
Proton TherapyGuest Editor: James M. Metz, MD, Associate Professor and Vice Chair, Clinical Division, Radiation Oncology, Hospital of the University of Pennsylvania
This issue provides a comprehensive review for practitioners on the current status of proton therapy, its scientific basis and current clinical applications along with reviews of the available clinical evidence, discussions of costs and technology development, and reviews of the issues in establishing a proton therapy center and the future development of proton therapy as a tool in clinical practice, both in academic centers and its future potential in community practice.conTenTS: Physics Considerations in Proton Therapy, Biology of Proton Therapy: Old and New Considerations, Develop-ing Clinical Trials and Registries for Proton Therapy, Prostate Cancer Treatment with Proton Therapy, Pediatric Cancer Treatment with Proton Therapy, Proton Therapy for Brain Tumors and Base of Skull Tumors, Developments in the Treatment of Thoracic Tumors with Proton Therapy, Building a Business Plan for Proton Therapy: All Things Considered, Feasibility of Community Based Proton Therapy Centers: Lessons Learned at OKC
december 2010 • 200 pp • hardcover • 978-1-936287-15-4 • e-book isbn • 978-1-617050-44-2 $85.00 / $72.25
lower gastrointestinal MalignanciesGuest Editors: edgar Ben-Josef, MD, Associate Professor, Department of Radiation Oncology, University of Michigan Medical Center, and Albert Koong, MD, PhD, Assistant Professor, Department of Radiation Oncology, Stanford University
Includes chapters on the evolution of systemic agents, neoadjuvant treatment, radiation therapy, chemoradiation therapy, rectal cancer and anal cancer cover- ing the vast majority of these tumors. The multidisciplinary nature of the articles provides readers with an up-to-date summary and a well-rounded review regarding these tumors and their care.conTenTS: Rectal Cancer: The Evolution of Modern Systemic Agents for Colorectal Cancer, Neoadjuvant Treatment of Rectal Cancer, Patient Selection for Adjuvant Therapy of Rectal Cancer, Intensity-Modulated Radiation Therapy in the Treatment of Rectal Cancer: Current Evidence and Directions for the Future, Short-Course Versus Long-Course Preopera-tive Radiation Therapy in Rectal Cancer, Management of T1/T2 Rectal Cancers with Transanal Excision and, Radiation Therapy, Neoadjuvant Chemoradiation and Complete Clinical Response for Distal Rectal Cancer, Predictors of Outcome in Rectal Cancer, Anal Cancer: Management of Anal Canal Cancer, Current Chemoradiation Strategies, Investigations into Intensity-Modulated Radiation Therapy, Predictors of Outcome for Anal Cancer, Management of Anal Dysplasia
Thoracic MalignanciesGuest Editor: steven e. schild, MD, Professor and Chairman, Department of Radiation Oncology, Mayo Clinic, Scottsdale
Thoracic malignancies addresses the multi-disciplinary nature of the care of these tumors. There is representation from radiation oncology, medical oncology, and surgery ensuring a well-rounded summarization of current practice. Included are chapters on lung cancer, esophageal cancer, and thymomas providing coverage of the vast majority of thoracic tumors. The multidisciplinary nature of the articles provides readers with an up-to-date summary and a well-rounded review regarding these tumors and their care.conTenTS: 1. Radiotherapy for Early Stage Non-Small Cell Carcinoma of the Lung, 2. Radiotherapy for the Locally Advanced Non-Small Cell Lung Cancer, 3. Radiotherapy for Limited Stage Small Cell Lung Cancer, 4. The Role of Radio-therapy for Extensive Stage and Recurrent Small Cell Lung Cancer, 5. Radiotherapy for the Palliation of Lung Cancer, 6. Radiotherapy as Adjuvant Therapy and Salvage Therapy after Resection of Non-Small Cell Lung Cancer, 7. Surgery for Non-Small Cell Lung Cancer, 8. Systemic Therapy for Lung Cell Cancer, 9. Radiotherapy for Esophageal Cancer, 10. Surgery for Esophageal Cancer, 11. Systemic Therapy for Esophageal Cancer, 11. Thymomas, Normal Tissue Toxicity, 12. Normal Tissue Toxicity
A New Cutting-Edge Review Publication in Radiation Medicine
EDITOR-IN-CHIEF: Charles R. Thomas, Jr., MD, Professor and Chairman, Depart-ment of Radiation Medicine, and Professor of Hematology/Oncology, Knight Cancer Insti-tute, Oregon Health Sciences University
FEATURES OF RADIATION MEDICINE ROUNDS INCLUDE:
In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Radiation Medicine
Each issue edited by an authority in that subject area
Each issue focused on a single major topic in Radiation Medicine, providing coverage of advances in radiation science, radiation medicine technology, radiation medicine practice, and assessment of recent quality and outcome studies
Radiation Medicine Rounds is available by subscription and individual issues. Individual subscriptions include print issue for volume year subscribed to and onlineaccess to all back issues.
North American Individual Subscription Rate: $199.00 / $161.50 International Individual Subscription Rate: $225.00 / $191.25
Published three times a year Radiation Medicine Rounds provides authoritative, thorough assessments of a wide range of “hot topics” and emerging new data for the entire specialty of radiation medicine.
Forthcoming December 2011
gynecologic cancerArno J. Mundt, MD, Professor and Chair, Department of Radiation Oncology, Catheryn Yashar, MD, Associate Professor, Chief of Breast and Gynecologic Radiation Services, Director of Medical School Education, Department of Radiation Oncology, loren Mell, MD, Assistant Professor of Radiation Oncology, Department of Radiation Oncology, all of University of California, San Diegodecember 2011 200 pp hardcover 978-1-936287-47-5 • e-book isbn 9781617050954 $85.00 / $72.25
head and neck cancerGuest Editors: Dwight e. Heron, MD, FACRO, Associate Professor of Radiation Oncology at the University of Pittsburgh School of Medicine, and Roy B. Tishler, MD, PhD, Associate Professor of Radiation Oncology, Harvard Medical School
This issue of Radiation medicine Rounds examines the latest advances in the use of radiation medicine in treatment of head and neck cancer. Head and neck cancer treatment has undergone major change over the course of the past few years and
head and Neck Cancer addresses current best practices in the light of the most recent evidence. All of the chapters are written by international experts in the field, address the common clinical scenarios in head and neck cancer and are multidisciplinary in scope. Chapters examining health services in head and neck cancer as well as factors influencing clinical decisions round out the coverage.conTenTS: I. Therapeutic Approaches: 1. Intensity Modulated Radiation Therapy for Head and Neck Cancer, 2. Concur-rent Therapy and Radiation for Head and Neck Cancer, 3. Targeted Therapy for Squamous Cell Carcinoma of the Head and Neck, 4. Induction Chemotherapy in Head and Neck Cancer, 5. Post-operative Radiation Therapy in Head and Neck Cancer, 6. Particle Therapy in Treatment of Head and Neck Cancer, 7. Optimizing Treatment Strategies in Recurrent Head and Neck Cancers, II. Health Services in Head and Neck Cancer: 8. Role of Outcomes Research in Head and Neck Cancer, 9. Palliative Care and Symptom Management in Head and Neck Cancer, 10. Toxicity Assessment and Reporting in Radiotherapy of Head and Neck Cancer, III. Factors Influencing Clinical Decisions: 11.Biomarkers and Molecular-targeted Therapeutics in Squamous Cell Carcinoma of the Head and Neck, 12. Image Guidance
August 2011 • 172 pp • hardback • 978-1-936287-36-9 • e-book isbn • 978-1-617050-71-8 • $85.00 / $72.25
Prostate cancerGuest Editors: Allen M. Chen, MD, Assistant Professor and Director, Residency and Fellowship Training Program, Department of Radiation Oncology, UC Davis Medical Center, and srinivasan Vijayakumar, MD, DMRT, FACR, Depart-ment Chair and Professor, Department of Radiation Oncology, University of Mississippi Medical Center
Prostate cancer is the most common cancer in males and radiation therapy is a
1110
Radiation Medicine Rounds
radiation Medicine rounds
demOS medical PubliShiNg | onColoGY | 2011
free shippinG* *on orders oVer $29.00
demOS medical PubliShiNg | onColoGY | 2011
WheN YOu Order ONliNe Or call 1-800-532-8663tO Order viSit www.demosmedpub.com
Blair A. Jobe, MD, Associate Professor of Surgery, Uni-versity of Pittsburgh Medical Center, Charles R. Thom-as, Jr., MD, Professor and Chairman of the Department of Radiation Medicine, Professor of Hematology/ Oncology, Knight Cancer Institute, Oregon Health Sciences Univer-sity, John G. Hunter, MD, Chairman of the Department of Surgery at Oregon Health Sciences University
Using a multi-disciplinary approach, Esophageal Cancer: Principles and Practice addresses the complexities encountered in the understanding and management of esophageal cancers. Written by the world’s leading experts in surgery, medical oncology, radiation oncology, gastroenterology, pathology, radiology, nutrition, nurse specialists, palliative medicine, and research relating to neoplasia of the esophagus, this text will serve as the definitive resource and enable prac-titioners to provide the best possible patient care. Presented in an accessible and useful format, this text is a valuable reference to all practitioners participating in the care of this high-needs population.
SPECIAL FEATURES INCLUDE: Complete coverage of the two most common tumors: squamous cell carcinoma and adenocarcinoma In-depth coverage of each topic with equal emphasis applied to both technical and
multidisciplinary aspects of treatment In-depth treatment of non-surgical topics in management at different phases of the disease Wide-ranging attention to the disease’s biologic aspects and basic science, contributing
Blair A. Jobe, MD, Associate Professor of Surgery, University of Pittsburgh Medical Center, Charles R. Thomas, Jr., MD, Professor and Chairman of the Department of Radiation Medicine, Professor of Hematology/ Oncology, Knight Cancer Institute, Oregon Health Sciences University, John g. Hunter, MD, Chairman of the Depart-ment Of Surgery at Oregon Health Sciences University
“it is a single, comprehensive source for current information regarding the biology, staging, and treatment of esophageal cancer, as well as an ex-cellent guide to the management of patients suffering from this disease.”—international Journal of radiation oncology biology and Physics, vol. 75, no. 5 “it is truly a well-written, practical, comprehensive text. it should serve as a helpful, handy reference to anyone involved in the treatment of this disease.” —gastrointestinal cancer research, January/February 2011, volume 4, issue 1
Recently Published in Oncology
Synopsis of clinical oncologyMichael D. Stubblefield, MD, Assistant Professor of Rehabilitation Medicine, Weill Medical College of Cornell, University Rehabilita-tion Medicine Service, Memorial Sloan-Kettering Cancer Center and Michael O’Dell, MD, Chief of Clinical Services, Department of Rehabilitation Medicine New York Presbyterian Hospital/Weill Cornell Medical Center, Professor of Clinical Rehabilitation Medicine, Weill Cornell Medical College
“This is an easy read for beginners struggling to understand the compli-cated discipline of oncology. in comparison to other books on oncology, this one is unique in its focus on professionals not familiar with the field.” —Doodys
Authored by some of the world’s leading cancer experts from wide ranging disciplines including oncology, radiation oncology, neurosurgery, orthopedic surgery, and radiology this compact volume provides authoritative state-of-the-art primer level overviews of the various cancer types, their evaluation, and treatment. Every aspect of oncology is covered with clear, up-to-date descriptions of the general principles and concepts fundamental to attaining a clinical appreciation of the foundations of cancer care. conTenT: I. PRInCIPles OF CAnCeR AnD CAnCeR TReATMenT: 1. Principles of Neoplasia, 2. Principles of Chemotherapy, 3. Principles of Immunotherapy, 4. Principles of Radiotherapy, 5. Principles of Neurosurgery in Cancer, 6. Principles of Orthopedic Surgery in Cancer, 7. Principles of Breast Surgery in Cancer, 8. Principles of Breast Reconstruc-tion in Cancer, 9. Principles of Spine Imaging in Cancer, 10. Principles of Plexus Imaging in Cancer, 11. Cancer Statistics, II. InTRODuCTIOn TO eVAluATIOn AnD TReATMenT OF MAlIgnAnCY: 12. Evaluation and Treatment of Breast Cancer, 13. Evaluation and Treatment of Prostate and Genitourinary Cancer, 14. Evaluation and Treatment of Lung and Bronchus Cancer, 15. Evaluation and Treatment of Colorectal Cancer, 16. Evaluation and Treatment of Melanoma, 17. Evaluation and Treatment of Lymphoma, 18. Evaluation and Treatment of Leukemia and Myelodysplasia, 19. Evaluation and Treatment of Primary Central Nervous System Tumors, 20. Evaluation and Treatment of Gynecologic Cancer, 21. Evaluation and Treatment of Head and Neck Cancer, 22. Evaluation and Treatment of Thyroid Cancer, 23. Evaluation and Treatment of Sarcoma, 24. Evaluation and Treatment of Primary Bone Tumors
oncology clinical TrialsSuccesful design, conduct, and analysis William Kevin Kelly, DO, Professor of Medical Oncology, Jefferson Medical College, and susan Halabi, PhD, Associate Professor, Depart-ment of Biostatistics and Bioinformatics, Duke University Medical Center
A well conceived, carefully designed and efficiently conducted clinical trial can produce results that change clinical practice overnight, deliver new oncology drugs and diagnostics to the marketplace, and expand the horizon of contemporary thinking about cancer biology. oncology Clinical Trials provides a comprehensive guide for both early-career
and senior oncology investigators into the successful design, conduct and analysis of an oncol-ogy clinical trial. oncology Clinical Trials covers how to formulate a study question, selecting a study population, study design of Phase I, II, and III trials, toxicity monitoring, data analysis and reporting, use of genomics, cost-effectiveness analysis, systemic review and meta-analysis, and many other issues. Many examples of real-life flaws in clinical trials that have been reported in the literature are included throughout. conTenTS: 1. Introduction: What Is a Clinical Trial?, 2. Historical Perspectives of Oncology Clinical Trials, 3. Ethical Principles Guiding Clinical Research, 4. Preclinical Drug Assessment, 5. Formulating the Question and Objectives, 6. Choice of Endpoints in Cancer Clinical Trials, 7. Design, Testing, and Estimation in Clinical Trials, 8. Design of Phase I Trials 9. Design of Phase II Trials, 10. Randomization, 11. Design of Phase III Trials, 12. Multiple Treatment Arm Trials, 13. Noninferiority Trials in Oncology, 14. Bayesian Designs in Clinical Trials, 15. The Trials and Tribulations of Writing an Investigator Initiated Clinical Study, 16. Data Collection, 17. Reporting of Adverse Event, 18. Toxicity Monitoring: hy, What, When?, 19. Interim Analysis of Phase III Trials, 20. Interpretation of Results: Data Analysis and Reporting of Results, 21. Statistical Considerations for Assessing Prognostic Factors in Cancer, 22. Pitfalls in Oncology Clinical Trial Designs and Analysis, 23. Biomarkers and Surrogate Endpoints in Clinical Trials, 24. Use of Genomics in Therapeutic Clinical Trials, 25. Imaging in Clinical Trials, 26. Pharmacokinetic and Pharmacodynamic Monitoring in Clinical Trials: When Is It Needed?, 27. Practical Design and Analysis Issues of Health Related Quality of Life Studies in International Randomized Controlled Cancer Clinical Trials, 28. Clinical Trials Considerations in Special Populations, 29. A Critical Reader’s Guide to Cost-Effectiveness Analysis, 30. Systemic Review and Meta-Analysis, 31. Regulatory Affairs: The Investigator-Initiated Oncology Trial, 32. The Drug Evolution Process in Oncology: FDA Perspective, 33. Industry Collaboration in Cancer Clinical Trials, 34. Defining the Roles and Responsibilities of Study Personnel, 35. Writing a Consent Form, 36. How Cooperative Groups Function, 37. Adaptive Design, 38. Where Do We Need to Go with Clinical Trials in Oncology?
cancer rehabilitationPrinciples and PracticeMichael D. Stubblefield, MD, Assistant Professor of Rehabilitation Medicine, Weill Medical College of Cornell, University Rehabilita-tion Medicine Service, Memorial Sloan-Kettering Cancer Center and Michael O’Dell, MD, Chief of Clinical Services, Department of Rehabilitation Medicine New York-Presbyterian Hospital/Weill Cornell Medical Center. Professor of Clinical Rehabilitation Medicine, Weill Cornell Medical College
“This book is a must-have for clinicians who wish to specialize in cancer rehabilitation.” —Doody’s reviews
“This book is a milestone and must-have for anyone involved in the care of those with cancer.“ —american Journal of Physical Medicine and rehabilitation
”...excellent accounts of cancer syndromes causing physical disability and pain, and well-done matched chapters that describe wider therapeutic approaches to help patients with these syndromes.” —international Journal of radiation oncology, biology, and Physiology, vol. 77, no. 5
This new comprehensive reference provides a state-of-the-art overview of the principles of cancer care and best practices for restoring function and quality of life to cancer survivors. Authored by some of the world’s leading cancer rehabilitation experts and oncology special-ists, the principles section provides primer level discussions of the various cancer types and their assessment and management. The practice section thoroughly explores the identification, evaluation, and treatment of specific impairments and disabilities that result from cancer and the treatment of cancer. This groundbreaking volume enables the entire medical team to provide superior care that results in a better quality of life for cancer survivors.2010 • 1,092 pp • hardcover • 978-1-933864-33-4 • e-book isbn • 978-1-935281-38-2 • $195.00 / $165.75
demOS medical PubliShiNg | onColoGY | 2011
free shippinG* *on orders oVer $29.00
demOS medical PubliShiNg | onColoGY | 2011
WheN YOu Order ONliNe Or call 1-800-532-8663tO Order viSit www.demosmedpub.com
Of Related Interest to Oncologists
effusion cytologya Practical guide to cancer diagnosisParvin ganjei-Azar, MD, Professor of Pathology, Director of Cytology Laboratories, Jackson Memorial Health System, Sylvester Comprehen-sive Cancer Center, Director of the Cytopathology Fellowship Program, Department of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, Mercè Jordà, PhD, Professor of Pathology, Department of Pathology, Miller School of Medicine, University of Miami, Director of Laboratory Services, Sylvester Comprehensive Cancer Center, University of Miami Hospitals, Miami, Florida, Awtar Krishan, PhD, Professor of Pathology, Department of Pathology, Miller School of Medicine, University of Miami, Miami, Florida
effusion Cytology is a practical manual in diagnosis and interpretation of body cavity fluid (BCF) specimens. This highly illustrated volume provides handy information for residents, fellows, and general pathologists with a step-by-step guide to evaluation of BCF specimens with the specific goal of identification of malignancies. Use of ancillary techniques such as im-munocytochemistry is discussed where appropriate. Special attention is given to the formula-tion of final cytologic reports of the diagnosis of difficult cases.conTenTS: 1. Body Cavity Fluid Cytology: Introduction, Source and Cellular Content, 2. General Diagnostic Criteria: Benign versus Malignant, 3. Types of Malignancy Based on Conventional Cytology and Immunocytochemistry, 4. Major Differential Diagnoses, 5. Detection of the Primary Site of Carcinomas, 6. Cerebrospinal Fluid Cytology, 7. Laboratory Techniques, 8. Flow Cytometry, Immunoassays and Molecular Techniques
february 2011 • 192 pp • softcover • 978-1-933864-65-5 • e-book isbn • 978-1-935281-41-2 • $85.00 / $72.25
brain Tumorsconsultant Pathology SeriesRichard Prayson, MD, Section Head for Neuropathology at Cleveland Clinic Main Campus, Cleveland, OH, Bette Kleinschmidt-DeMasters, MD, Head of Neuropathology at the University of Colorado, Denver, and Professor of Pathology at the University of Colorado, Denver School of Medicine, Mark Cohen, MD, Director of the Division of Neuropathology, University of Cleveland and Professor of Pathology, Case Western Reserve University, School of Medicine
Surgical neuropathology is a challenging arena for many pathologists, due in large part to a relative lack of experience of most pathologists in this area compared to other areas of surgical pathology. Brain Tumors is intended to address this need with cases drawn from the surgical neuropathology practices of the authors.
This volume provides examples of over 100 brain tumors, running the gamut from the very common to the rare. Each example is presented in a case based format and the wide variety of cases presented covers the entire scope of brain tumors and offers the opportunity to review both the basics for the beginner or relatively inexperienced pathologist and also offers experi-enced pathologists the chance to see some of the rare entities.2010 • 318 pp • hardcover • 978-1-933864-69-3 • e-book isbn • 978-1-935281-36-8 • $140.00 / $119.00
Metastatic carcinomas of unknown originMark R. Wick, MD, Professor of Pathology, University of Virginia Health System
“…this is a unique and concise textbook that incorporates a framework for how to approach metastatic carcinomas of unknown origin. it covers the spectrum of presentation of these lesions through treatment and postmortem valida-tion.”—The aSc bulletin, volume Xlvii, number 6, november 2010
metastatic Carcinomas of unknown origin is the first comprehen-sive, fully illustrated discussion of the clinical features, pathologic attributes, and treatment approaches of metastatic carcinomas of unknown origin (MCUOs). This unique text provides a framework for approaching these complex issues, with contributions from international experts in the field of MCUOs.Contents: Clinical Findings, Clinical Presentations of MCUOs, Paraneolastic Syndromes Associated with MCUOs, Neurologic Paraneoplasias, Dermatologic Paraneoplasias, Non-neurologic, Non- dermatologic Paraneoplasias, Pathologic Evaluation of Metastases, Histology and Cytopathology, Electron Microscopy, Immunohistology, Serum Tumor Markers, Tissue Microarrays and Gene Chips, Clinical Localization of Prim ary Tumors, Endoscopic Evaluation of the Head and Neck, Endoscopic Evaluation of the Gastrointestinal Tract, Radiological Assessments, Treatment, Prognosis, and Future Prospects, Chemotherapy, Surgical Therapies, Postmortem Validation Studies
biliary Tract and gallbladder cancerdiagnosis and therapy Charles R Thomas, Jr, MD, Professor and Chairman of the Department of Radiation Medicine, Oregon Health & Science University, Clifton David Fuller, MD, Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio
“...an excellent choice for any physician seeking a comprehensive, multidisci-plinary, and cutting-edge review of biliary tract and gallbladder cancer.” —uzma D. Siddiqui, MD, Journal of clinical gastroenterology, volume 43, number 9, october 2009
Biliary Tract and gallbladder Cancer: diagnosis and Therapy is a comprehensive and definitive discussion of all aspects of the treatment of malignant tumors of the gallbladder and biliary tract. This is the first book to examine these cancers in such depth, as rapid advances in surgical oncology and radiotherapeutic approaches have demanded the full coverage this text provides. conTenTS: section I: general Considerations: Epidemiology of Gallbladder and Biliary Tract Neoplasms, Role of Growth Factor Signaling Pathways, section II: Diagnostic Approaches, Histopathology and Molecular Pathogenesis of Gallbladder Cancer, Histopathology and Pathogenesis of Biliary Tract Cancer, Novel Biomarkers for Biliary Tract Cancer, Pathological Staging of Gallbladder and Biliary Tract Cancer, Overview of Current Diagnostic Imaging Strate-gies, Imaging of Hepatic Transplantation for Biliary Tract Cancer, Magnetic Resonance Imaging, Functional Imaging, Computed Tomography, section III: Therapeutic Approaches, Radiofrequency Ablation, Chemoembolization, Surgical Management of Intrahepatic Biliary Tract Cancer, Surgical Management of Extrahepatic Biliary Tract Cancer, Surgical Management of Gallbladder Cancer, Systemic Therapy for Biliary Tract Cancer, Radiation Therapy, 3D-Con-formal and Intensity-Modulated Radiation Therapy, Brachytherapy, Image-Guided Radiation Therapy and Stereotactic Body Radiation Therapy, Symptom Management and Palliation, Section IV: Summary, Future Directions.
brain Metastasisa multidisciplinary approach lawrence R. Kleinberg, MD, Associate Professor of Radiation Oncology, The Johns Hopkins University School of Medicine
Brain metastasis: a multidisciplinary approach conveys vital information about management strategies, outcomes, and techniques to enable oncologists to provide a full range of appropriate care and counseling to patients with meta-static spread to the brain.
Brain metastasis includes complete discussions for all situations in which radiosurgery might be recommended, including for the treatment of gross brain metastasis, for the prevention of tumor-related injury of brain function, and as an alternative to whole-brain radiotherapy. conTenTS: Neurologic Manifestations of Brain Metastasis, Recognition, Evolution, and Management, Radiation Therapy for Brain Metastases, Prognosis of Patients with Brain Metastases who Undergo Radiation Therapy, Surgical Management of Intracranial Metastases, Radiosurgery for Brain Metastases, The Role of Targeted Therapy without Whole Brain Radiotherapy, Chemotherapy for Brain Metastasis: What We Know and What We Don’t, Supportive Care: Controlling Symptoms of Brain Metastasis and Diminishing the Toxicities of Treatment, Radiosurgery for Spinal Tumors
combining Targeted biological agents with radiotherapycurrent Status and future directions William small, Jr, MD, Professor of Radiation Oncology and Vice-Chairman of the Department of Radiation Oncology, Northwestern University
“...comprehensive reviews of current studies and planned studies... well- written.” —Doody’s reviews
Combining Targeted Biological agents with Radiotherapy: Current status and future directions is an overview of the current state of
clinical and pre-clinical research in combining radiotherapy with targeted biological agents to fight cancer. The text provides a general overview of targeted agents, reviews the current clinical trials, and includes a look at the future of this state-of-the-art practice. conTenTS: Targeted Therapies: Definitions, Limitations, and Future Directions, Epidermal Growth Factor (EGFR) Receptors, Vascular Epithelial Growth Factor (VEGF) Receptors, Dermatologic Manifestations of Targeted Therapies, Dermatologic Manifestations of Targeted Therapies, Radiolabeled Monoclonal Antibody Therapies, Targeted Therapies in Malignant Gliomas, Targeted Therapies in Head and Neck Cancer, Targeted Therapies in Lung Cancer, Targeted Therapies in Pancreatic Cancer, Targeted Therapies in Cervical Cancer, Targeted Therapies in Endometrial Cancer
us CustoMers reCeiVe free shippinG*When You order online
Use Discount Code ONC 2011 when ordering online Save 15%
Please send me: Title
•Add $7.50 for the first book; $2.50 for each additional book
for standard UPS shipping within North AmericaFor international orders in the UK, Europe, Middle East, Australia and New Zealand please contact customer service at [email protected] Call 1-800-532-8663 for expidiated shipping rates
•
•
Send to: 11 West 42nd Street, New York, NY 10036 Phone: 212.683.0072 Fax: 212.941.7842
Many Demos Medical Titles are Now
available in E-book format.
to find your favorite Demos titles in a variety of formats.
ISBN Quantity
Subtotal
Tax
Shipping
Total
Price
www. demosmedpub.com
*on orders more than $29.00
Prices subject to change without notice
Order Confirmation
Enclosed is a check or money order in full payment.(Make all checks payable to DEMOS. Payment must be made in U.S. dollars drawn on a U.S. bank)
Charge my account VISA MC AMEX Discover
Method of Payment
Residence or Business
Please complete the shipping information below
DEMOS MEDICAL PUBLISHING
Visit Amazon, bn.com, and Google Books
Save 15% Plus Free ShippingWhen You Order Online
USE DISCOUNT CODE ONC 2011
Name (please print)
Signature
Card Number Exp. Date
Email for confirmation of order
Country Telephone Fax
Address
City State Zip
Affiliation Department
New York residents add appropriate sales taxTotal amount payable
Please send me the books indicated Total OrderShipping / Handling
Free Shipping and Discounts apply only to orders shipped within the United States
